Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company focused on developing and commercializing innovative medicines aimed at improving the lives of patients suffering from immune-mediated diseases. The company's lead investigational drug, reproxalap, is a first-in-class treatment that is in late-stage development for dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing other product candidates for a range of conditions, including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, autoimmune diseases, and certain cancers. The company's efforts are dedicated to addressing unmet medical needs through the development of next-generation therapies.
Helio Vision
Acquisition in 2019
Helio Vision, Inc. is a biotechnology company based in Waltham, Massachusetts, founded in 2016 to address proliferative vitreoretinopathy (PVR), a condition that causes abnormal scarring and potential blindness following retinal detachment. The company focuses on developing a therapy that employs sustained intravitreal exposure to methotrexate, a medication known for its anti-proliferative and anti-inflammatory properties. This innovative approach aims to interrupt the scarring process that often complicates post-operative recovery for patients undergoing retinal surgery. Helio Vision operates as a subsidiary of Aldeyra Therapeutics, Inc. and was co-founded by physicians associated with the Massachusetts Eye and Ear Infirmary, who are committed to improving outcomes for individuals affected by this rare and challenging eye disorder.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.